Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.
Location: Switzerland, Zurich
Employees: 11-50
Total raised: $14.05M
Investors 6
| Date | Name | Website |
| - | Verve Vent... | verve.vc |
| - | Venture Ki... | venturekic... |
| - | EFI Lake G... | lakegeneva... |
| - | VentureLab | venturelab... |
| 07.09.2024 | Club degli... | clubdeglin... |
| - | StartAngel... | startangel... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 12.09.2023 | - | $5.06M | - |
| 03.12.2021 | Series B | $5.67M | - |
| 16.09.2018 | Series A | $3.32M | - |
Mentions in press and media 26
| Date | Title | Description |
| 10.11.2023 | Zahlreiche Startups zuoberst auf dem Treppchen | Gleich drei Startups gewannen beim Design Preis Schweiz in ihren jeweiligen Kategorien. Das Zürcher Startup Hylomorph entwickelt Membranen und Beutel, die die Fremdkörperreaktion auf chirurgische Implantate reduzieren. Im Rahmen eines Fors... |
| 10.11.2023 | Zahlreiche Startups zuoberst auf dem Treppchen | |
| 12.09.2023 | Swiss Medtech startup Hylomorph raises CHF 4.5 million in Series B2 financing round | This significant funding marks a major milestone for Hylomorph as it continues pursuing its mission to make a substantial impact on patients’ care. The investment will help the Zurich-based ETH spin-off Hylomorph expand its product portfoli... |
| 05.09.2023 | Hylomorph secures CHF 4.5m ahead of market launch | |
| 28.04.2023 | Swiss Accelerator: Innosuisse supports 53 companies with CHF112 million | |
| 03.12.2021 | Hylomorph secures CHF 5.2 million series-B round | |
| 03.12.2021 | Hylomorph secures a CHF 5.2 million Series-B round led by Geneva Smart Invest and Start Angels Network | Hylomorph secures a CHF 5.2 million Series-B round led by Geneva Smart Invest and Start Angels Network 03.12.2021 08:17, Isabelle Mitchell linkedIn facebook twitter instagram youtube --> Hylomorph, a rapidly growing clinical-stage medtec... |
| 03.12.2021 | Hylomorph secures a CHF 5.2 million Series-B round led by Geneva Smart Invest and Start Angels Network | These “booster injections” aim at safely bringing the company to FDA and CE mark approval of its product portfolio, beginning with the blockbuster Hylomate®. The existing investors made a strong statement with their continued support by co-... |
| 07.06.2021 | Encouraging results from Hylomorph’s clinical trial | |
| 04.02.2020 | Hylomorphs Schutzhülle für Implantate erstem Patienten eingesetzt |
Show more